title: Changes in intraocular pressure and tear secretion in patients given 5 mg solifenacin for the treatment of overactive bladder.
abstract: OBJECTIVE
  To investigate the effect of solifenacin succinate on intraocular pressure (IOP) and dry eye in patients with overactive bladder (OAB).
  
  
  METHODS
  The study was conducted prospectively between October 2014 and November 2015. A total of 93 female OAB patients with a mean age of 48.59 ± 11.28 years (range 19-75 years) were evaluated. A full ophthalmic examination, including the Schirmer I test and IOP measurements, was conducted. Solifenacin succinate (5 mg/day) was started orally. All procedures were repeated at the 4- and 12-week follow-up, and the effects and side effects were documented.
  
  
  RESULTS
  No statistically significant difference was observed in IOP (p = 0.282, p = 0.189) and tear secretion (p = 0.122, p = 0.071) values from the baseline (day 0) to the 12th week in OAB patients using solifenacin succinate. Solifenacin succinate treatment was terminated in 3 patients owing to dry eye in 1 patient, increased IOP in 1 patient, and systemic side effects in 1 patient. Constipation and dry mouth at various rates were the most common systemic side effects observed.
  
  
  CONCLUSIONS
  Solifenacin succinate is useful in eliminating OAB symptoms in female patients, but can cause systemic side effects. It had no significant side effects on tear secretion (Schirmer I) and IOP. We concluded that solifenacin succinate could be reliably used in pure OAB patients without comorbidity in terms of dry eye and IOP. We believe that prospective studies with larger series are still needed to reach a definite conclusion.
authors.affiliation: Department of Urology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey. a.turkoglu@hotmail.com.
authors.forename: Ali Riza
authors.initials: AR
authors.lastname: Turkoglu
authors.affiliation: Department of Ophthalmology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.
authors.forename: Neslihan Parmak
authors.initials: NP
authors.lastname: Yener
authors.affiliation: Department of Urology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.
authors.forename: Soner
authors.initials: S
authors.lastname: Coban
authors.affiliation: Department of Urology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.
authors.forename: Muhammet
authors.initials: M
authors.lastname: Guzelsoy
authors.affiliation: Department of Urology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Demirbas
authors.affiliation: Department of Family Medicine, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.
authors.forename: Hakan
authors.initials: H
authors.lastname: Demirci
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D015352:Dry Eye Syndromes / Q000150:complications; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D009301:Nasolacrimal Duct; D011446:Prospective Studies; D000069464:Solifenacin Succinate / Q000008:administration & dosage / Q000009:adverse effects*; D013666:Tears / Q000187:drug effects / Q000378:metabolism*; D053201:Urinary Bladder, Overactive / Q000150:complications / Q000188:drug therapy*
chemical_list: D018727:Muscarinic Antagonists; D000069464:Solifenacin Succinate
keywords: Anticholinergic; Dry eye; Intraocular pressure; Side effects; Solifenacin succinate; Women